SCHEDULE: FMR LLC Amends Ultragenyx Pharma Stake to 3.5%
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, disclosing a 3.5% beneficial ownership stake in Ultragenyx Pharma Inc. as of December 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson beneficially own 3,347,890.21 shares of Ultragenyx Pharma Inc. common stock.
- This ownership represents 3.5% of the total class of securities.
- FMR LLC holds sole voting power over 3,279,798.00 shares and sole dispositive power over 3,347,890.21 shares.
- Abigail P. Johnson, as a Director, Chairman, and CEO of FMR LLC, is deemed to have sole dispositive power over 3,347,890.21 shares.
- The filing is an Amendment No. 1 to a previous Schedule 13G statement.
- The beneficial ownership is held in the ordinary course of business and not for the purpose of changing or influencing control of Ultragenyx Pharma Inc.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard regulatory disclosure of beneficial ownership and does not contain information regarding the issuer's operational performance or strategic direction.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that this filing is a routine disclosure of an institutional investor's passive stake in a biotechnology company, not indicative of broader industry trends or competitive shifts.
Key Dates
| Date | Description |
|---|---|
| January 3, 2023 | Effective date of Power of Attorney for FMR LLC. |
| January 26, 2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| December 31, 2025 | Date of event which requires the filing of this statement (measurement date for beneficial ownership). |
| February 4, 2026 | Date of signing and filing of this Schedule 13G amendment. |
Keywords
Ultragenyx Pharma Inc., FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.